[title missed]

Corresponding author: Duan Ruisheng, 13832140261@126.com

DOI: 10.12201/bmr.202508.00009

•  

  Abstract: : Alzheimers disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline, with its pathological hallmarks primarily including the deposition of β-amyloid (Aβ) plaques and neurofibrillary tangles caused by hyperphosphorylated Tau protein. In recent years, monoclonal antibody drugs targeting Aβ have become a major focus in AD treatment research. In July 2024, the U.S. FDA approved Donanemab as a novel immunotherapy drug, which specifically binds to formed amyloid plaques and effectively clears Aβ deposits by activating the complement system and microglia-mediated phagocytosis. Clinical studies have demonstrated that Donanemab significantly slows cognitive decline in early-stage AD patients while substantially reducing treatment duration compared to traditional regimens. This article provides a systematic review of Donanemabs mechanism of action, pharmacokinetic profile, clinical research progress, dosing regimen, and safety concerns, and explores its clinical application prospects, aiming to offer new insights and references for AD treatment.

  Key words: : Donanemab; Alzheimers disease; β-amyloid; monoclonal antibody; neurodegenerative disease

  Submit time: 5 August 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Zhao shanshan, Shi Haolin, Wang yingshuai, Wang yanli. A Study on Improved Swin Transformer for Alzheimers Disease MRI Image Classification. 2025. doi: 10.12201/bmr.202505.00029

  The guiding significance of quantitative EEG parameters in adjusting treatment plans for Alzheimers disease. 2025. doi: 10.12201/bmr.202501.00062

  SUI XIN, SONG JUAN, BAO YANAN, LIN YU, MAN ZITENG, CHENG TIANTIAN, YANG HONGYAN. 1. School of Pharmacy,Qiqihar Medical University,Qiqihar 161006,China2. Affiliated Third Hospital,Qiqihar Medical University,Qiqihar 161006,China. 2024. doi: 10.12201/bmr.202407.00036

  Huang Ling Xia. . 2025. doi: 10.12201/bmr.202508.00033

  XIANG Hongying, LING Yingchun. Analysis of the predictive value of quantitative parameters of electroencephalogram and serum miR-146a-5p for cognitive impairment in Alzheimers disease patients. 2024. doi: 10.12201/bmr.202412.00027

  王馨雨, ZHANG Shujuan. Research progress of GLP-2 in non-alcoholic fatty liver disease. 2025. doi: 10.12201/bmr.202502.00018

  lubo, LvYingYing, ChenYuYan. . 2025. doi: 10.12201/bmr.202506.00054

  Liu Yanan, Zhan Ming, Han Fei. Research Progress and Prospects of Finerenone in the Treatment of Diabetic Nephropathy. 2024. doi: 10.12201/bmr.202410.00033

  chengjiawei, lijinhu, siwenshuo, liutao, niuguoqi. . 2025. doi: 10.12201/bmr.202504.00061

  ZHANG Mingming, LI Xiaohui. Research progress on platelet-leukocyte aggregates in the pathogenesis of Kawasaki disease. 2025. doi: 10.12201/bmr.202502.00058

• ID	Submit time	Number	Download
  1	2025-06-30	bmr.202508.00009V1	Download

• Public  Anonymous  To author only Submit Comments